AstraZeneca's heart-condition drug gets US FDA approval for new dosage

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved a new dose of its drug to treat patients with a history of heart attack beyond the first year.

The FDA approved Brilinta (ticagrelor) at a new 60 milligram dose to be taken beyond a year after a heart attack.

The company said the FDA nod confirms the drug, Brilinta, is approved to reduce the rate of cardiovascular death, heart attack and stroke in patients with acute coronary syndrome (ACS) or a history of heart attacks.